Update of the Guideline on Chronic Pruritus Developed by the Guideline Subcommittee “Chronic Pruritus” of the European Dermatology Forum Subcommittee Members: Prof. Dr. Elke Weisshaar, Heidelberg (Germany) Prof. Dr. Sonja Ständer, Münster (Germany) Prof. Dr. Erwin Tschachler, Wien (Austria) Prof. Dr. Torello Lotti, Florence (Italy) Prof. Dr. Johannes Ring, Munich (Germany) Prof. Dr. Laurent Misery, Brest (France) Dr. Markus Streit, Aarau (Switzerland) Prof. Dr. Thomas Mettang, Wiesbaden (Germany) Prof. Dr. Jacek Szepietowski, Wroclaw (Poland) Prof. Dr. Joanna Wallengren, Lund (Sweden) Dr. Peter Maisel, Münster (Germany) Prof. Dr. Uwe Gieler, Gießen (Germany) Prof. Dr. Malcolm Greaves (Singapore) Prof. Dr. Ulf Darsow, Munich (Germany) Prof. Dr. Julien Lambert, Antwerp (Belgium) Members of EDF Guideline Committee: Prof. Dr. Werner Aberer, Graz (Austria) Prof. Dr. Dieter Metze, Münster (Germany) Prof. Dr. Martine Bagot, Paris (France) Dr. Kai Munte, Rotterdam (Netherlands) Prof. Dr. Nicole Basset-Seguin, Paris (France) Prof. Dr. Gilian Murphy, Dublin (Ireland) Prof. Dr. Ulrike Blume-Peytavi, Berlin (Germany) Prof. Dr. Martino Neumann, Rotterdam (Netherlands) Prof. Dr. Lasse Braathen, Bern (Switzerland) Prof. Dr. Tony Ormerod, Aberdeen (UK) Prof. Dr. Sergio Chimenti, Rome (Italy) Prof. Dr. Mauro Picardo, Rome (Italy) Prof. Dr. Alexander Enk, Heidelberg (Germany) Prof. Dr. Johannes Ring, Munich (Germany) Prof. Dr. Claudio Feliciani, Rome (Italy) Prof. Dr. Annamari Ranki, Helsinki (Finland) Prof. Dr. Claus Garbe, Tübingen (Germany) Prof. Dr. Berthold Rzany, Berlin (Germany) Prof. Dr. Harald Gollnick, Magdeburg (Germany) Prof. Dr. Rudolf Stadler, Minden (Germany) Prof. Dr. Gerd Gross, Rostock (Germany) Prof. Dr. Sonja Ständer, Münster (Germany) Prof. Dr. Vladimir Hegyi, Bratislava (Slovakia) Prof. Dr. Eggert Stockfleth, Berlin (Germany) Prof. Dr. Michael Hertl, Marburg (Germany) Prof. Dr. Alain Taieb, Bordeaux (France) Prof. Dr. Dimitrios Ioannidis, Thessaloniki (Greece) Prof. Dr. George-Sorin Tiplica, Bucharest (Romania) Prof. Dr. Gregor Jemec, Roskilde (Denmark) Prof. Dr. Nikolai Tsankov, Sofia (Bulgaria) Prof. Dr. Lajos Kemény, Szeged (Hungary) Prof. Dr. Elke Weisshaar, Heidelberg (Germany) Dr. Gudula Kirtschig (Germany) Prof. Dr. Sean Whittaker, London (UK) Prof. Dr. Robert Knobler, Wien (Austria) Prof. Dr. Fenella Wojnarowska, Oxford (UK) Prof. Dr. Annegret Kuhn, Münster (Germany) Prof. Dr. Christos Zouboulis, Dessau (Germany) Prof. Dr. Marcus Maurer, Berlin (Germany) Prof. Dr. Torsten Zuberbier, Berlin (Germany) Chairman of EDF Guideline Committee: PD Dr. Alexander Nast, Berlin (Germany) Expiry date: 01/2017 EDF Guidelines Secretariat to PD Dr. Nast: Bettina Schulze, Klinik für Dermatologie, Venerologie und Allergologie, Campus Charité Mitte, Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany phone: ++49 30 450 518 062, fax: ++49 30 450 518 911, e-mail: bettina.schulze@charité.de CONFLICT OF INTEREST STATEMENTS Conflicts of interests_p.1 Remark: no entry means “none” The Work Under Consideration for Publication Misery, Weisshaar, Lotti, Darsow, Laurent Elke Torello Ulf 1 Grant 2 Consulting fee or honorarium 3 Support for travel to meetings for the study or other purposes 4 Fees for participation in review activities, such as data monitoring boards, statistical analysis, end point committees, and the like 5 Payment for writing or reviewing the manuscript 6 Provision of writing assistance, medicines, equipment, or administrative support 7 Other * This means money that your institution received for your efforts on this study. Relevant financial activities outside the submitted work 1 Board membership Almirall, President World Novartis Health Academy Publishing House, Zurich, CH; Editor, Dermatologic Therapy; Executive, Vitiligo Research Foundation, USA 2 Consultancy Pierre Fabre EV Laser, Italy; GLG, USA CLINUVEL, Australia; Applied Biology, Inc, Irvine, CA, USA¸EVERETT LABORATOIRES Inc. USA; BIOSKIN EVOLUTION ©® 3 Employment University of Rome “G.Marconi”, 1 Rome, Italy 4 Expert testimony Advance Medical, Spain 5 Grants/grants BASF, Uriage Stiefel pending Laboratoriums, Förderverein Juckreizfor- schung e.V., Fresenius 6 Payment for Astellas, DGUV, BGAG lectures including Novartis Dresden, service on BGMS, BGFE, speakers bureaus Philipps-Univ. Marburg, Neurodermitis- Akademie Hessen, Thüringen, SAMA, Basilea GmbH, Stiefel Labs. GmbH, Intendis GmbH, Essex Pharma GmbH, Novartis GmbH, Sebapharma GmbH 7 Payment for Pierre Fabre Fresenius manuscript preparation 8 Patents (planned, pending or issued) 9 Royalties 10 Payment for development of educational presentations 11 Stock/stock options 12 Travel/accommodat MCAS, AMEC, ions/meeting COSMODERM, expenses unrelated CUTICON, MIB to activities listed** ESCAD, PANARAB 13 Other (err on the side of full disclosure) * This means money that your institution received for your efforts. ** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line. Other relationships 1 Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially 2 influencing, what you wrote in the submitted work? 3 Conflicts of interests_p.2 Remark: no entry means “none” The Work Under Consideration for Publication Ring, Johannes Wallengren, Tschachler, Streit, Joanna Erwin Markus 1 Grant 2 Consulting fee or honorarium 3 Support for travel to meetings for the study or other purposes 4 Fees for participation in review activities, such as data monitoring boards, statistical analysis, end point committees, and the like 5 Payment for writing or reviewing the manuscript 6 Provision of writing assistance, medicines, equipment, or administrative support 7 Other * This means money that your institution received for your efforts on this study. Relevant financial activities outside the submitted work 1 Board membership Novartis, Pfizer, Merck 2 Consultancy Chanel S.A. 3 Employment University of Munich 4 Expert testimony 5 Grants/grants ALK Abelló, Chanel S. A. Centocor pending Allergopharma, Almirall Hermal, Astellas, Bencard, Bogen-Idec, Galderma, Glaxo Smith- Kline, Leo, MSD, Novartis, Phadia, PLS Design, Stallergenes 6 Payment for Convatec, lectures including Coloplast, service on Johnson & speakers bureaus Johnsons, Essex 4 7 Payment for manuscript preparation 8 Patents (planned, pending or issued) 9 Royalties 10 Payment for development of educational presentations 11 Stock/stock options 12 Travel/accommodat ions/meeting expenses unrelated to activities listed** 13 Other (err on the side of full disclosure) * This means money that your institution received for your efforts. ** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line. Other relationships 1 Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work? 5 Conflicts of interests_3 Remark: no entry means “none” The Work Under Consideration for Publication Maisel, Lambert, Greaves, Mettang, Peter Julien Malcolm Thomas 1 Grant 2 Consulting fee or honorarium 3 Support for travel to meetings for the study or other purposes 4 Fees for participation in review activities, such as data monitoring boards, statistical analysis, end point committees, and the like 5 Payment for writing or reviewing the manuscript 6 Provision of writing assistance, medicines, equipment, or administrative support 7 Other * This means money that your institution received for your efforts on this study. Relevant financial activities outside the submitted work 1 Board membership 2 Consultancy MEDA, FMC Germany PFIZER, MSD, ABBVIE, JANSEN- CILAG, LEO PHARMA 3 Employment 4 Expert testimony 5 Grants/grants pending 6 Payment for GSK, MEDA, FMC Germany lectures including PFIZER, MSD, Roche service on ABBVIE, speakers bureaus JANSEN- CILAG, LEO PHARMA 7 Payment for FMC Germany manuscript preparation 8 Patents (planned, pending or issued) 9 Royalties 10 Payment for development of 6 educational presentations 11 Stock/stock options 12 Travel/accommodat ions/meeting expenses unrelated to activities listed** 13 Other (err on the side of full disclosure) * This means money that your institution received for your efforts. ** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line. Other relationships 1 Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work? 7 Conflicts of interests_4 Remark: no entry means “none” The Work Under Consideration for Publication Szepietowski, Gieler, Ständer, Jacek Uwe Sonja 1 Grant 2 Consulting fee or honorarium 3 Support for travel to meetings for the study or other purposes 4 Fees for participation in review activities, such as data monitoring boards, statistical analysis, end point committees, and the like 5 Payment for writing or reviewing the manuscript 6 Provision of writing assistance, medicines, equipment, or administrative support 7 Other * This means money that your institution received for your efforts on this study. Relevant financial activities outside the submitted work 1 Board membership 2 Consultancy Abbott, Almirall, Allmiral Basilea, Bayer- Creabilis, Intendis, Daiichi Sankyo Galderma, Kneipp, Merz Glaxo-Smith Nerre Kline, Merz